Board of directors
Roland Andersson, Chairman of the board
Roland Andersson is professor of surgery and vice dean for the medical faculty at Lund University. He is co-founder of Reccan Diagnostics AB, as well as several other biotech companies, including Probi Ltd and Bioactive Polymers in Lund Ltd. He has also been CEO of Nordic Biotechnology Ltd and is member of the board of Bioactive Polymers.
Daniel Ansari is co-founder of Reccan Diagnostics AB and holds the position as scientific coordinator. Dr Ansari is employed as researcher at Lund University, as well as surgeon at SUS, Skåne University Hospital, and holds a MD and a PhD from Lund University. He has extensive research experience in the field of surgery and diagnostics, with special focus on translational research in pancreatic cancer.
Christer Fåhraeus is CEO of EQL Pharma AB and a serial entrepreneur, having founded and developed several successful companies in biotech and engineering. He is Chairman of the board of FlatFrog Laboratories AB, Longboat explorers AB and Respiratorius, as well as board member in CellaVision AB and EQL Pharma AB. He is former CEO of Cellavision AB, Anoto Group AB, FlatFrog Laboratories and Agellis Groups AB. He holds a B.Sc. with majors in both bioengineering and mathematics from Lund University, a MSc in Bioengineering from UCSD, as well as an honorary PhD in Engineering from Lund University.
György Marko-Varga is professor and head of the division of clinical protein science and imaging at Lund University, professor at Tokyo Medical University in Japan as well as co-founder of Reccan Diagnostics. Prof. Marko-Varga has almost twenty years of experience from Big Pharma and a long list of filed patent applications. His access to novel technological platforms and biobanking is of fundamental value for Reccan Diagnostics.
Christine Widstrand is Executive Vice President at LU Innovation System AB and responsible for the Life Science portfolio. She holds a PhD in Analytical Chemistry from Lund University. With a background as CEO and founder of several Biotech Companies, she has gained over twenty years of experience in business development, venture capital raising, international sales and marketing, licensing and organisational and quality management. Dr Widstrand has many years of experience in board work, both as a member and as a Chairman.
Lars Grundemar is Adjunct Professor of Clinical Pharmacology at Lund University as well as Head of Experimental Medicine at Ferring Pharmaceuticals. He holds a MD and a PhD, and his previous experience include positions at Pfizer/Pharmacia (USA/Italy), AstraZeneca (Sweden) and Novartis (Switzerland). He has built up Experimental Medicine /Translational medicine functions in multiple therapeutic areas (eg. CNS, oncology and inflammation), developed test for companion diagnostics and crafted strategies for personalized/precision medicine across therapeutic applications.